Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: adriamycin
Drug: epirubicin
Drug: fluorouracil

First Posted Date: 2004-07-12

Last Posted Date: 2022-08-11

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 2722

Registration Number: NCT00087178

Locations: 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

and more 599 locations

Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-07

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 704

Registration Number: NCT00002953

Locations: 🇬🇧
University Birmingham, Birmingham, England, United Kingdom
🇬🇧
Norfolk & Norwich Hospital, Norwich, England, United Kingdom
🇿🇦
Groote Schuur Hospital, Cape Town, Cape Town, South Africa

and more 16 locations

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-07-01

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002691

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: Filgrastim (G-CSF)
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Paclitaxel
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2004-07-01

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00002837

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: asparaginase
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: etoposide
Drug: leucovorin calcium
Drug: liposomal cytarabine
Drug: mercaptopurine
Drug: mesna
Drug: methotrexate
Drug: therapeutic hydrocortisone
Drug: thiotepa
Drug: vincristine sulfate
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-07-01

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 156

Registration Number: NCT00002704

Locations: 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

and more 67 locations

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: bleomycin sulfate
Drug: CHOP regimen
Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: cytarabine
Drug: prednisone
Drug: etoposide
Drug: idarubicin
Drug: ifosfamide
Drug: mesna
Drug: methylprednisolone
Drug: mitoxantrone hydrochloride
Drug: vincristine sulfate

First Posted Date: 2004-06-30

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00002565

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇧🇷
Faculdade de Medicina do ABC, Sao Paulo, Brazil
🇨🇱
Clinica Alemana, Santiago, Chile

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

Phase 1

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-06-28

Last Posted Date: 2013-11-06

Lead Sponsor: St. Vincent Medical Center - Los Angeles

Registration Number: NCT00002482

Locations: 🇺🇸
St. Vincent Medical Center - Los Angeles, Los Angeles, California, United States

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

First Posted Date: 2004-06-28

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00005854

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 1 locations

Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: cyclophosphamide
Drug: etoposide
Drug: BCNU

First Posted Date: 2004-06-25

Last Posted Date: 2013-06-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 147

Registration Number: NCT00005613

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-06-25

Last Posted Date: 2023-09-07

Lead Sponsor: University of Nebraska

Registration Number: NCT00004197

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy